$MBRX
Moleculin Biotech, Inc.

2020 Q3 Form 10-Q Financial Statement

#000165961720000196 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.660M $1.650M $1.480M
YoY Change -0.6% 11.49% 21.31%
% of Gross Profit
Research & Development $4.435M $3.329M $2.099M
YoY Change 59.25% 58.6% -50.39%
% of Gross Profit
Depreciation & Amortization $57.00K $52.00K $49.00K
YoY Change 11.76% 6.12% 600.0%
% of Gross Profit
Operating Expenses $6.151M $5.034M $3.632M
YoY Change 36.45% 38.6% -33.46%
Operating Profit -$6.151M -$5.034M -$3.632M
YoY Change 36.45% 38.6% -33.46%
Interest Expense $2.750M -$5.100M $2.410M
YoY Change 2015.38% -311.62% 630.3%
% of Operating Profit
Other Income/Expense, Net $10.00K $17.00K $0.00
YoY Change 100.0% -100.0%
Pretax Income -$3.395M -$10.11M -$1.220M
YoY Change -22.38% 728.69% -76.22%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.395M -$10.11M -$1.221M
YoY Change -18.09% 728.17% -76.18%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$331.7K -$1.020M -$172.6K
COMMON SHARES
Basic Shares Outstanding 61.70M shares 60.40M shares 45.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.80M $16.73M $18.70M
YoY Change -16.94% -10.53% 59.56%
Cash & Equivalents $12.80M $16.73M $18.70M
Short-Term Investments
Other Short-Term Assets $257.0K $436.0K $1.510M
YoY Change -91.92% -71.13% 29.06%
Inventory
Prepaid Expenses $1.507M
Receivables
Other Receivables
Total Short-Term Assets $15.25M $19.75M $20.20M
YoY Change -17.95% -2.24% 56.7%
LONG-TERM ASSETS
Property, Plant & Equipment $522.0K $238.0K $401.0K
YoY Change 45.81% -40.65% 1442.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.89M $11.63M $11.65M
YoY Change 0.69% -0.18% 4.28%
TOTAL ASSETS
Total Short-Term Assets $15.25M $19.75M $20.20M
Total Long-Term Assets $11.89M $11.63M $11.65M
Total Assets $27.14M $31.38M $31.85M
YoY Change -10.7% -1.49% 32.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.343M $1.918M $1.257M
YoY Change -57.87% 52.59% -25.0%
Accrued Expenses $2.095M $1.821M $1.390M
YoY Change 88.57% 31.01% -24.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.438M $3.739M $9.591M
YoY Change -69.08% -61.02% 133.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.240M $12.01M $170.0K
YoY Change 2980.0% 6964.71% -94.69%
Total Long-Term Liabilities $9.240M $12.01M $170.0K
YoY Change 2980.0% 6964.71% -94.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.438M $3.739M $9.591M
Total Long-Term Liabilities $9.240M $12.01M $170.0K
Total Liabilities $12.68M $15.75M $9.762M
YoY Change 10.98% 61.35% 33.4%
SHAREHOLDERS EQUITY
Retained Earnings -$54.30M -$50.90M -$31.60M
YoY Change 51.68% 61.08% 46.98%
Common Stock $68.71M $66.49M $53.69M
YoY Change 25.57% 23.84% 40.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.47M $15.63M $22.09M
YoY Change
Total Liabilities & Shareholders Equity $27.14M $31.38M $31.85M
YoY Change -10.7% -1.49% 32.36%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$3.395M -$10.11M -$1.221M
YoY Change -18.09% 728.17% -76.18%
Depreciation, Depletion And Amortization $57.00K $52.00K $49.00K
YoY Change 11.76% 6.12% 600.0%
Cash From Operating Activities -$5.370M -$4.940M -$5.340M
YoY Change 61.26% -7.49% 54.34%
INVESTING ACTIVITIES
Capital Expenditures -$340.0K -$20.00K -$10.00K
YoY Change 3300.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$340.0K -$20.00K -$10.00K
YoY Change 3300.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.770M 10.01M 15.28M
YoY Change 3440.0% -34.49% 641.75%
NET CHANGE
Cash From Operating Activities -5.370M -4.940M -5.340M
Cash From Investing Activities -340.0K -20.00K -10.00K
Cash From Financing Activities 1.770M 10.01M 15.28M
Net Change In Cash -3.940M 5.050M 9.930M
YoY Change 19.76% -49.14% -809.29%
FREE CASH FLOW
Cash From Operating Activities -$5.370M -$4.940M -$5.340M
Capital Expenditures -$340.0K -$20.00K -$10.00K
Free Cash Flow -$5.030M -$4.920M -$5.330M
YoY Change 51.51% -7.69% 54.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001659617
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37758
dei Entity Registrant Name
EntityRegistrantName
MOLECULIN BIOTECH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4671997
dei Entity Address Address Line1
EntityAddressAddressLine1
5300 Memorial Drive,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 950
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77007
dei City Area Code
CityAreaCode
713
CY2019Q4 us-gaap Assets Current
AssetsCurrent
13484000 USD
dei Local Phone Number
LocalPhoneNumber
300-5160
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61704290 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16734000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10735000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3015000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2749000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
19749000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
238000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
316000 USD
CY2020Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
245000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
287000 USD
CY2020Q2 us-gaap Assets
Assets
31380000 USD
CY2019Q4 us-gaap Assets
Assets
25235000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1918000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2153000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1821000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1417000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3739000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3570000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
220000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
276000 USD
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
11792000 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5818000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
15751000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
9664000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60403164 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60403164 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45727700 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45727700 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
60000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
46000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
66428000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55055000 USD
CY2020Q2 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
23000 USD
CY2019Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
31000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3075000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50882000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39561000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
15629000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31380000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25235000 USD
CY2020Q2 us-gaap Revenues
Revenues
0 USD
CY2019Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3329000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2099000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6535000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5031000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1653000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1484000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3463000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000 USD
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
97000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
5034000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
3632000 USD
us-gaap Operating Expenses
OperatingExpenses
10096000 USD
us-gaap Operating Expenses
OperatingExpenses
8203000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5034000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3632000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10096000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8203000 USD
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5099000 USD
CY2019Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2407000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1254000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2936000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000 USD
CY2019Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10112000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1221000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11321000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5262000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59483267 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42393031 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54707132 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35765790 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10112000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1221000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11321000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5262000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
25000 USD
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10087000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1223000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11329000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5275000 USD
us-gaap Net Income Loss
NetIncomeLoss
-11321000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5262000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
97000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
805000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
666000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1254000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2936000 USD
mbx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-95000 USD
mbx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
6000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
266000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
667000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-235000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
295000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1097000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9275000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9194000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1557000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15298000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19240000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15303000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20802000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-13000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5999000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11561000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10735000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7134000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16734000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1209000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18695000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
1000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
15000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15571000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
709000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
566000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
397000 USD
CY2020Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-33000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15292000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
336000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10007000 USD
CY2020Q2 mbx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
9000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
408000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10112000 USD
CY2020Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
25000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
15629000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14272000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
617000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4041000 USD
CY2019Q1 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-11000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14682000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
302000 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3584000 USD
CY2019Q2 mbx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4731000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
318000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1221000 USD
CY2019Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
-2000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
22092000 USD
mbx Number Of Drug Technologies
NumberOfDrugTechnologies
3 technology
mbx Number Of Drug Candidates
NumberOfDrugCandidates
5 candidate
mbx Number Of Cancer Treatment Approaches
NumberOfCancerTreatmentApproaches
3 approach
mbx Number Of Clinical Trials For Drug Candidates
NumberOfClinicalTrialsForDrugCandidates
2 clinicalTrial
mbx Number Of Clinical Trials For Drug Candidates
NumberOfClinicalTrialsForDrugCandidates
2 clinicalTrial
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50900000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.
CY2020Q2 mbx Vendor Prepayment And Deposits
VendorPrepaymentAndDeposits
1352000 USD
CY2019Q4 mbx Vendor Prepayment And Deposits
VendorPrepaymentAndDeposits
1857000 USD
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1214000 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
352000 USD
CY2020Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
10000 USD
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
10000 USD
CY2020Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
3000 USD
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
436000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
529000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3015000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2749000 USD
CY2020Q2 mbx Vendor Prepayment And Deposits Expansion Of Production Commitments
VendorPrepaymentAndDepositsExpansionOfProductionCommitments
1100000 USD
CY2019Q4 mbx Vendor Prepayment And Deposits Expansion Of Production Commitments
VendorPrepaymentAndDepositsExpansionOfProductionCommitments
1500000 USD
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2020Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2019Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
400000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000 USD
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21200000 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19800000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9500000 shares
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
800000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
436000 USD
CY2020Q2 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
349000 USD
CY2019Q4 mbx Accrued Drug Manufacturing Cost
AccruedDrugManufacturingCost
49000 USD
CY2020Q2 mbx Accrued Legal Regulatory Professional Fees Current
AccruedLegalRegulatoryProfessionalFeesCurrent
220000 USD
CY2019Q4 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
201000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1821000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
272000 USD
CY2020Q2 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
135000 USD
CY2019Q4 mbx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
93000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000 USD
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
99000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
99000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000 USD
CY2020Q2 mbx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
33000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1417000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
408000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
318000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
805000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
666000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3836000 shares
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.59
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.26
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1548503 shares
CY2020Q2 mbx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
1.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
90000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.06
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.24
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
mbx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0.89
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.06
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3906000 shares
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.58
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.24
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
500000 USD
CY2020Q2 mbx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Aggregated Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAggregatedFairValue
100000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2200000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
400000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
8000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
58000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
16000 USD
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000 USD
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
9000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
26000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
7000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
14000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
12000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
40000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
27000 USD
us-gaap Lease Cost
LeaseCost
81000 USD
us-gaap Lease Cost
LeaseCost
54000 USD
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
10000 USD
us-gaap Sublease Income
SubleaseIncome
21000 USD
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
33000 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
13000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
66000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
21000 USD
CY2020Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
110000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
68000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
138000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
105000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
56000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10000 USD
CY2020Q2 mbx Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
0 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
377000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
330000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2019Q3 mbx Sale Of Stock Maximum Potential Consideration Received Per Transaction
SaleOfStockMaximumPotentialConsiderationReceivedPerTransaction
15000000.0 USD

Files In Submission

Name View Source Status
0001659617-20-000196-index-headers.html Edgar Link pending
0001659617-20-000196-index.html Edgar Link pending
0001659617-20-000196.txt Edgar Link pending
0001659617-20-000196-xbrl.zip Edgar Link pending
a2020q2ex311-xnextgen.htm Edgar Link pending
a2020q2ex312-xnextgen.htm Edgar Link pending
a2020q2ex321-xnextgen.htm Edgar Link pending
a2020q2ex322-xnextgen.htm Edgar Link pending
exhibit101-mdaamendno3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbx-20200630.htm Edgar Link pending
mbx-20200630.xsd Edgar Link pending
mbx-20200630_cal.xml Edgar Link unprocessable
mbx-20200630_def.xml Edgar Link unprocessable
mbx-20200630_g1.jpg Edgar Link pending
mbx-20200630_htm.xml Edgar Link completed
mbx-20200630_lab.xml Edgar Link unprocessable
mbx-20200630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending